Item 7.01 Regulation FD Disclosure.
On September 30, 2021, Alzamend Neuro, Inc. (the "Company") issued a press
release to announce that the U.S. Food and Drug Administration has issued a
written response to the Company's meeting request relating to its Type B
Pre-Investigational New Drug application for the clinical development of AL002.
A copy of the press release is furnished herewith as Exhibit 99.1 and is
incorporated by reference herein.
The information contained in this Current Report shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or incorporated by reference in any filing under the Securities
Act of 1933, as amended (the "Securities Act") or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing. The
furnishing of the information in this Current Report on Form 8-K is not intended
to, and does not, constitute a representation that such furnishing is required
by Regulation FD or that the information contained in this Current Report on
Form 8-K constitutes material investor information that is not otherwise
publicly available.
The Securities and Exchange Commission encourages registrants to disclose
forward-looking information so that investors can better understand the future
prospects of a registrant and make informed investment decisions. This Current
Report on Form 8-K and exhibits may contain these types of statements, which are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, and which involve risks, uncertainties and
reflect the registrant's judgment as of the date of this Current Report on Form
8-K. Forward-looking statements may relate to, among other things, operating
results and are indicated by words or phrases such as "expects," "should,"
"will," and similar words or phrases. These statements are subject to inherent
uncertainties and risks that could cause actual results to differ materially
from those anticipated at the date of this Current Report on Form 8-K. Investors
are cautioned not to rely unduly on forward-looking statements when evaluating
the information presented within.
Item 9.01 Exhibits and Financial Statements.
(d) Exhibits:
Exhibit
No. Description
99.1 Press Release issued on September 30, 2021
101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in
Inline XBRL (Inline eXtensible Business Reporting Language).
104 Cover Page Interactive Data File (embedded within the Inline XBRL document
and included in Exhibit 101).
© Edgar Online, source Glimpses